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IMPORTANCE Patients and clinicians need to accurately assess the risks and benefits of pars
plana vitrectomy for proliferative diabetic retinopathy, but clinical trial data may not reflect
real-world experience.
OBJECTIVE To prospectively audit the complications of vitrectomy for proliferative diabetic
retinopathy and help establish benchmarks.
DESIGN, SETTING, AND PARTICIPANTS Royal College of Ophthalmologists’ National
Ophthalmology Database study of 939 eyes of 834 patients undergoing primary vitrectomy
for proliferative diabetic retinopathy at 16 different vitreoretinal units in the United Kingdom.
Data were obtained for the period from January 2001 to November 2010.
INTERVENTIONS Pars plana vitrectomywith or without delamination/segmentation.
MAIN OUTCOMES ANDMEASURES Descriptions of the primary procedures performed,
intraoperative complication rate, and proportion of eyes undergoing further surgery. An
exploratory analysis of visual outcomewas undertaken, with visual success and visual loss
defined as a gain or reduction of 0.3 logMAR or more, respectively (approximately 2 Snellen
lines), 6 to 12 months after surgery.
RESULTS Of 420 eyes (among 408 patients) that underwent vitrectomywithout
delamination, the intraoperative complication rate was 13.1% (95% CI, 10.2%-16.7% [55 of
420 eyes]), with 126 eyes (30.0%) requiring an intravitreal tamponade and 49 eyes (11.7%)
undergoing further vitrectomy (median follow-up, 6.9months); 17.9% of 127 phakic eyes
developed cataracts within a year, with 63.6% achieving visual success and 8.2% visual loss.
Of 519 eyes (among 463 patients) that underwent vitrectomywith delamination, the
intraoperative complication rate was 30.4% (95% CI, 26.6%-34.5% [158 of 519 eyes]), with
299 eyes (57.6%) requiring an intravitreal tamponade and 78 eyes (15.0%) undergoing
further vitrectomy (median follow-up, 7.1 months); 21.2% of 126 phakic eyes developed
cataracts within a year, with 62.8% achieving visual success and 14.9% visual loss.
CONCLUSIONS AND RELEVANCE Diabetic vitrectomy has an appreciable complication rate,
particularly if delamination or segmentation are required. Nonetheless, the data available on
visual acuity suggest that a majority of patients achieve clinically meaningful gains in vision.
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P roliferative diabetic retinopathy can lead to vitreoushemorrhage and, in severe cases, tractional retinal de-tachment. Not all patients need surgery, but persisting
vitreous hemorrhage or tractional retinal detachment involv-
ing or threatening the macula are 2 of the most common
indications for pars plana vitrectomy (PPV).1 For vitreous
hemorrhage, PPV primarily aims to clear the visual axis by
removing blood-stained vitreous. For tractional retinal
detachment, PPV is combined with delamination or seg-
mentation of the preretinal fibrovascular membranes, to
relieve retinal traction.
UsingtheRoyalCollegeofOphthalmologists’NationalOph-
thalmologyDatabase (RCOphthNOD),weaim todescribedia-
betic PPV techniques and surgical complication rates to allow
benchmarking.TheRCOphthNODcollects anonymized, prag-
matic surgical audit data from hospitals across the United
Kingdom, with the aim of providing benchmark surgical
outcomes for both surgeons and patients.1-6
Methods
Data Extraction
Our database study relates to primary vitrectomies for dia-
betic vitreous hemorrhage or tractional retinal detachment
that were performed during the period from January 2001 to
November 2010, using data supplied to the RCOphth NOD, as
reported previously.1,2,4,5 Data were extracted from 13 vitreo-
retinal units using the same electronic medical record (EMR)
system (Medisoft Ophthalmology; Medisoft Limited) up to
November 2010, and from 3 vitreoretinal units using a non-
commercial database (VITREOR database; Guy’s and St
Thomas’ NHS Foundation Trust) up to October 2013. Data
analysis started in November 2013, but the majority of the
analysis was conducted in 2014, with additional analysis con-
ducted in 2015. Our study was conducted in accordance with
the Declaration of Helsinki and the United Kingdom’s Data
Protection Act. The lead clinician and Caldicott Guardian
(who oversees data protection) at each hospital gave written
approval to extract the data. Anonymized database analyses
of this type do not require ethical permission because they
are viewed as audit or service evaluation.7 Eyes were divided
into those undergoing PPV with or without delamination/
segmentation of fibrovascular membranes.
Complications of Pars Plana Vitrectomy
The EMRs required surgeons to record whether or not there
were any surgical complications, before they could save the
operation note. If a complication occurred, then the surgeon
had to select fromaprepopulated list ofwell-recognized com-
plications specific to that operation or select “other” and rec-
ord thecomplicationusing free text.All thehospitalsusing the
commercial EMR for vitreoretinal surgical procedures re-
corded cataract surgeryusing the samesystem,while the cen-
ters thatused thenoncommercial databasehada tendency for
postvitrectomy cataract operations to be performed in other
units, so it was not possible to accurately determine the post-
vitrectomycataract rate for thesepatients. Therefore, only the
commercial EMR datawere used to estimate the incidence of
postvitrectomy cataract surgery.
Statistical Analysis
Theoperationswere grouped intodiabetic vitrectomywithor
withoutdelamination.Althoughour studyprimarily aimed to
provide benchmark complication rates (usingmandated data
collectionduring surgery), some centers alsoused theEMR to
recordpostoperativevisual acuity (VA), andanexploratoryVA
analysiswasundertakenusing the logMARscale,where count
fingers (CF), handmotions (HM), light perception (LP), andno
LP (NLP) were assigned values of 2.1, 2.4, 2.7, and 3.0,
respectively.1,4,5 Visual acuity values less than 6 weeks after
primary PPV were excluded. The main VA result was consid-
ered as the best-recorded VA between 6 and 12 months after
surgery, with data also displayed graphically for the best-
recorded VA within 1 to 4 weeks, 1 to 3 months, and 3 to 6
months after surgery. Visual success at 6 to 12monthswasde-
fined as a gain of 0.3 logMAR or more (approximately
2 Snellen lines), and visual loss was defined as a loss of 0.30
logMAR or more.
The time to postvitrectomy cataract surgery was mod-
eled using the Kaplan-Meier8 method, in which the failure
eventwas cataract surgery. Eyeswere censoredat the last date
onwhich follow-updataof any typewere recorded in theEMR,
if thepatientshadnothadcataract surgery.Eyeswith less than
3months of follow-up, with lens touch during vitrectomy, or
requiring a further vitrectomy were excluded. Potential dif-
ferencesbetween the2 treatmentgroups in termsof theequal-
ity of survival functions for postvitrectomy cataract surgery,
thepresenceofoperativecomplications,andvisual successand
loss were compared using the log-rank test or the Fisher ex-
act testwhen appropriate. For each treatment group, postvit-
rectomycataractsurgerywas investigatedbytheuseofgaswith
primary vitrectomy and age at primary vitrectomy using the
log-rank test or the t test with theWald approximation when
appropriate. ThePearsonχ2 test and the t testwereusedwhen
appropriate to compare the sex, ethnicity, and age at vitrec-
tomybetweenpatientswithandpatientswithout recordedVA
data, and to compare thepresentingVAbetweenpatientswith
andpatientswithouteligiblepostoperativeVAdata.ThePvalue
At a Glance
• The United Kingdom’s National Ophthalmology Database
prospectively collects pragmatic “real-world” surgical data,
including 11 618 vitreoretinal surgical procedures.
• This report details the subset of 420 eyes undergoing diabetic
vitrectomy and 519 eyes undergoing diabetic vitrectomywith
delamination or segmentation.
• The intraoperative complication rate for diabetic vitrectomy
without delamination was 13.1%, with 11.7% of eyes requiring
further vitrectomy, and 70 of 110 eyes (63.6%) gaining
2 Snellen lines.
• The intraoperative complication rate for diabetic vitrectomywith
delamination was 30.4%, with 15.0% eyes requiring further
vitrectomy, and 59 of 94 eyes (62.8%) gaining 2 Snellen lines.
• Diabetic vitrectomy has an appreciable complication rate, but
despite this, a majority of patients gain vision.
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threshold used for statistical significance was .05. All analy-
ses were conducted using Stata, version 11 (StataCorp), ex-
cept for 95%CIs, whichwere calculated using Confidence In-
terval Analysis.9
Results
Patient Demographics
Therewere 15 667 vitreoretinal surgical procedures recorded
intheRCOphthNODover thestudyperiod.Of these,939(6.0%)
were primary PPVs for diabetes (939 eyes, 834 patients, and
64 surgeons). Of these 939 PPVs, 482 (51.3%)were for the left
eye and 457 (48.7%) were for the right eye; 420 (44.7%) vit-
reoretinal surgicalprocedureswerediabeticvitrectomieswith-
out delamination, and 519 (55.3%)were diabetic vitrectomies
with delamination (Table 1). In total, 105 patients had surgery
performed on both their eyes, 68 of whom had both eyes in
the same surgical treatment group.
Surgical Technique and Anesthesia
Of the420diabeticvitrectomieswithoutdelamination (among
408patients), 76 (18.1%)werePPVsonly,344 (81.9%)werePPVs
that included intraoperative laser surgery, 126 (30.0%) were
PPVs that included an intravitreal tamponade (33 with sulfur
hexafluoride, 9 with hexafluoroethane, 16 with octafluoro-
propane, 54with air, and 14with silicone oil), and 99 (23.6%)
were PPVs combined with cataract surgery. General anesthe-
sia was used for 150 diabetic vitrectomies (35.7%), and local
anesthesia was used for 268 diabetic vitrectomies (63.8%) (3
with sedation); for 2 diabetic vitrectomies (0.5%), anesthesia
was not recorded.
Of the510diabeticvitrectomieswithdelamination (among
463patients), 42 (8.1%)werePPVsonly, 477 (91.9%)werePPVs
that required intraoperative laser surgery, 299 (57.6%) were
PPVs that required an intravitreal tamponade (98 with sulfur
hexafluoride, 25 with hexafluoroethane, 66 with octafluoro-
propane, 53with air, and57with siliconeoil), and 105 (20.2%)
were PPVs combined with cataract surgery. General anesthe-
sia was used for 333 diabetic vitrectomies with delamination
(64.2%), and local anesthesiawasused for 183diabetic vitrec-
tomieswith delamination (35.3%) (4with sedation); for 3 dia-
betic vitrectomies with delamination (0.6%), anesthesia was
not recorded.
Intraoperative Complications
Of the 939 PPVs, 726 (77.3%) were recorded as having no
intraoperative complication. The overall operative complica-
tion rate was 22.7% (95% CI, 20.1%-25.5% [213 of 939 PPVs]).
The 2 most commonly reported complications were iatro-
genic tear (213 PPVs [19.4%]) and lens touch (13 PPVs [1.4%])
(Table 2).
The overall complication rates were 13.1% (95% CI,
10.2%-16.7% [55 of 420 PPVs]) for the diabetic vitrectomies
without delamination and 30.4% (95% CI, 26.6%-34.5% [158
of 519 PPVs]) for the diabetic vitrectomieswith delamination,
which were more likely to have an intraoperative complica-
tion (odds ratio, 2.9 [95%CI, 2.1-4.1]; P < .001), mainly owing
to havingmore iatrogenic tears (144 of 519 PPVs [27.7%] vs 38
of 420 PPVs [9.0%]; P < .001); otherwise, the individually re-
portedcomplicationswerenot significantlydifferent (Table2).
Excluding the complications associatedwith cataract sur-
gery, we found that the overall complication rate attributable
to PPV was 21.7% (95% CI, 19.2%-24.5% [204 of 939 PPVs]).
Table 1. Patient Demographics
Characteristic
Pars Plana Vitrectomy
TotalWithout Delamination With Delamination
Eyes, No. 420 519 939
Operation, No. (%) of eyes
First 393 (93.6) 441 (85.0) 834 (88.8)
Second 27 (6.4) 78 (15.0) 105 (11.2)
First operation, No. of patients 393 441 834
Sex, No. (%) of patients
Male 226 (57.5) 250 (56.7) 476 (57.1)
Female 167 (42.5) 191 (43.3) 358 (42.9)
Ethnicity, No. (%) of patients
White 222 (56.5) 176 (39.9) 398 (47.7)
Asian 10 (2.5) 10 (2.3) 20 (2.4)
African-Caribbean 9 (2.3) 38 (8.6) 47 (5.6)
Other 1 (0.3) 7 (1.6) 8 (1.0)
Not recorded 151 (38.4) 210 (47.6) 361 (43.3)
Age, y, median (IQR) 63.8 (52.2-72.9) 54.4 (42.4-64.2) 58.2 (46.2-69.2)
Diabetes mellitus, No. (%) of patients
Type 1 99 (25.2) 138 (31.3) 237 (28.4)
Type 2 185 (47.1) 220 (49.9) 405 (48.6)
Not recorded 109 (27.7) 83 (18.8) 192 (23.0) Abbreviation: IQR, interquartile
range.
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The complication rate (excluding cataract-related complica-
tions) was 11.7% (95% CI, 8.9%-15.1%) for diabetic vitrecto-
mies without delamination (49 of 420 PPVs) and 29.9% (95%
CI, 26.1%-33.9%) for diabetic vitrectomieswith delamination
(155 of 519 PPVs) (odds ratio, 3.2 [95% CI, 2.2-4.6]; P < .001).
Further PPV
At least 1 furtherPPVwasperformedon 127of939eyes (13.5%)
(95% CI, 11.5%-15.9%) after a median of 2.8 months (inter-
quartile range, 2 days to 7.1 years) after primary surgery, com-
prising49of420eyes (11.7%) thatunderwentPPVwithoutde-
laminationand78of519eyes (15.0%) thatunderwentPPVwith
delamination (P = .08). Retinal detachment occurred in 19 of
939 eyes (2.0%) (95% CI, 1.3%-3.1%) after a median of 2.7
months (interquartile range, 25 days to 1.1 years), including 7
of 420 eyes (1.7%) after PPV without delamination and 12 of
519 eyes (2.3%) after PPV with delamination (P = .32).
Postvitrectomy Cataract Surgery
Of the 939 eyes, 686 were excluded from the postvitrectomy
cataract surgery analysis: 238 because they were not re-
corded in the commercial EMR, 66 because of previous cata-
ract surgery, 149 because they had combined cataract sur-
gery, 5 because of lens touch, 48 because they underwent a
further PPV, and 180 because they had less than 3 months of
follow-up. Of the remaining 253 eyes eligible for analysis, the
median follow-upwas 1.2 years (interquartile range, 3months
to 4.3 years), and 58 (22.9%) were subsequently recorded as
havingcataract surgery (28afterPPVwithoutdelaminationand
30 after PPV with delamination). The 1-, 2-, and 3-year post-
vitrectomy cataract surgery rates were 17.9%, 28.0%, and
44.1%, respectively, for 127 eyes that underwent PPVwithout
delamination and 21.2%, 34.6%, and 43.9%, respectively, for
126 eyes that underwent PPV with delamination (P = .43)
(Figure 1).
For both groups of patients, those who underwent post-
vitrectomy cataract surgery were older than those who did
not; the mean ages at vitrectomy were 67.1 vs 59.5 years, re-
spectively (P = .002), for thepatientswhounderwentPPVwith-
outdelaminationand60.3vs47.8years, respectively (P < .001),
for the patients who underwent PPV with delamination. The
useofgasduringdiabeticvitrectomywithoutdelaminationdid
not have a significant effect on subsequent cataract surgery;
26 of 113 gas-filled eyes (23.0%) and 2 of 14 eyes without gas
(14.3%) underwent cataract surgery (P = .64). For the pa-
tients who underwent PPV with delamination, a higher pro-
portion of eyes that had gas subsequently underwent cata-
ract surgery: 14 of 34 eyes that had gas (41.2%) vs 16 of 92 eyes
that did not have gas (17.4%) (P = .047).
Visual Acuity
Of the 939 eyes, 730 (77.7%) had a presenting VA recorded in
the EMR. Of these 730 eyes, the median and mean VAs were
CF and 1.55 logMAR (Snellen equivalent of 20/693), respec-
tively (interquartile range, −0.30 logMAR to NLP), which
included 157 eyes with a VA of CF (21.5%), 182 eyes with a
VA of HM (24.9%), 34 eyes with a VA of LP (4.7%), and 4
eyes with a VA of NLP (0.5%). The logMAR VA (and Snellen
equivalent) was 0.30 (20/40) or better for 71 eyes (9.7%) and
1.00 (20/200) or worse for 499 eyes (68.4%). Of the 730
eyes with a presenting VA in the EMR, 204 were excluded
from postoperative VA analysis (53 had no further VA data,
and 151 had <6 weeks of follow-up). Of 526 eyes eligible for
postoperative VA analysis, the median and mean presenting
logMAR VAs (and Snellen equivalents) were CF and 1.54 (20/
693), respectively. Of these 526 eyes, 204 had VA outcomes
at 6 to 12 months after surgery with a median and mean VA
of 0.50 and 0.76 logMAR, respectively (with Snellen equiva-
lents of 20/63 and 20/115, respectively). The logMAR VA
(Snellen equivalent) was 0.30 (20/40) or better for 88 of
Table 2. Intraoperative Complications
Complication Status
Pars Plana Vitrectomy
Total
(N = 939) P Valuea
Without Delamination
(n = 420)
With Delamination
(n = 519)
Operations, No.
With no reported complications 365 (86.9) 361 (69.6) 726 (77.3) <.001
With reported complications 55 (13.1) 158 (30.4) 213 (22.7)
Reported complications, No. of operations
Iatrogenic tear 38 (9.0) 144 (27.7) 182 (19.4) <.001
Lens touch 9 (2.1) 4 (0.8) 13 (1.4) .09
Posterior capsule rupture
(no vitreous loss)b
6 (1.4) 3 (0.6) 9 (1.0) .31
Conjunctival buttonhole 2 (0.5) 1 (0.2) 3 (0.3) .59
Retinal hemorrhage 0 (0.0) 3 (0.6) 3 (0.3) .26
Choroidal/suprachoroidal hemorrhage 2 (0.5) 0 (0.0) 2 (0.2) .20
Corneal epithelial abrasion 2 (0.5) 0 (0.0) 2 (0.2) .20
Subretinal hemorrhage 0 (0.0) 1 (0.2) 1 (0.1) >.99
Nuclear/epinuclear fragments
into vitreousb
1 (0.2) 0 (0.0) 1 (0.1) .45
Subretinal heavy liquid 0 (0.0) 1 (0.2) 1 (0.1) >.99
Other 0 (0.0) 3 (0.6) 3 (0.3) .26
Total No.c 61 160 221
a Derived from the Fisher exact test
comparing the rate of a specific
complication between the 2
treatment groups.
b Lens-related complications
occurring in eyes with combined
cataract surgery.
c More than 1 intraoperative
complication could be reported for
each operation, and therefore the
sum of the individual complication
percentages exceeds the
percentage of operations with a
complication.
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204 eyes (43.1%) and 1.00 (20/200) or worse for 52 of
204 eyes (25.5%).
Of the 420 eyes that underwent PPV without delamina-
tion, 323 (76.9%) had a presenting VA. Themedian andmean
VAswere CF and 1.64 logMAR (Snellen equivalent of 20/873),
respectively (interquartile range,−0.30 logMARtoNLP).Of214
eyes eligible for postoperative VA analysis, the median pre-
senting VA was CF, and the mean VA was 1.58 logMAR (Snel-
len equivalent of 20/760). Of these 214 eyes, 110 had a me-
dianandmeanVAof0.50and0.74 logMAR, respectively (with
Snellen equivalents of 20/63 and 20/110, respectively) 6 to 12
months after surgery (Figure 2). The logMAR VA (Snellen
equivalent)was0.30 (20/40)orbetter for50of 110eyes (45.5%)
and 1.00 (20/200) or worse for 27 of 110 eyes (24.5%).
Of the519eyes thatunderwentPPVwithdelamination,407
(78.4%) had a presenting VA recorded in the EMR; the me-
dian and mean VAs were 1.60 and 1.49 logMAR, respectively
(Snellen equivalents of 20/796 and 20/618, respectively) (in-
terquartile range, 0.00 to LP). Of 312 eyes eligible for postop-
erativeVAanalysis, themedianandmeanpresentingVAswere
1.60 and 1.52 logMAR, respectively (Snellen equivalents of
20/796 and 20/662, respectively). At 6 to 12months after sur-
gery, themedian andmeanVAswere0.5 and0.78 logMAR, re-
spectively (Snellen equivalents of 20/63 and 20/120, respec-
tively) for 94 eyes (Figure 3). The logMAR VA (Snellen
Figure 1. Rates of Postvitrectomy Cataract Surgery
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Figure 2. Visual Acuity in Eyes That Underwent Pars Plana Vitrectomy
Without Delamination
NLP
HM
1.80 (20/1280)
0.90 (20/160)
0.00 (20/20)
LP
CF
1.50 (20/640)
1.20 (20/320)
0.60 (20/80)
0.30 (20/40)
−0.30 (20/10)
0
(214 Eyes)
0.25-1
(86 Eyes)
6-12
(110 Eyes)
3-6
(95 Eyes)
Vi
su
al
 A
cu
ity
, l
og
M
AR
 (S
ne
lle
n 
Eq
ui
va
le
nt
)
Months Since Surgery
1-3
(122 Eyes)
(n = 3)
(n = 11)
(n = 58)
(n = 43)
(n = 2)
(n = 8)
(n = 8)
(n = 1)
(n = 2)
(n = 10)
(n = 4)
(n = 1)
(n = 8)
(n = 5)
(n = 1)
(n = 3)
(n = 6)
(n = 5)
Box plots of logMAR visual acuity before and after surgery. The horizontal line in
themiddle of each box indicates themedian, while the top and bottom borders
of the boxmark the 75th and 25th percentiles, respectively. The whiskers above
and below the boxmark the 90th and 10th percentiles, respectively. The
numbers in parentheses refer to the numbers of eyes with visual acuity at the
level shown on the y-axis, for that time period (shown on the x-axis). The points
beyond the whiskers are outliers beyond the 90th percentile. CF indicates
counting fingers; HM, handmotions; LP, light perception; and NLP, no light
perception.
Figure 3. Visual Acuity in Eyes That Underwent Pars Plana Vitrectomy
With Delamination
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Box plots of logMAR visual acuity before and after surgery. The horizontal line in
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fingers; HM, handmotions; LP, light perception; and NLP, no light perception.
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equivalent)was0.30 (20/40)orbetter for38of94eyes (40.4%)
and 1.00 (20/200) or worse for 25 of 94 eyes (26.6%).
At 6 to 12months after surgery, visual success (≥0.30 log-
MAR gain) was achieved by 129 of the 204 eyes (63.2% [95%
CI, 56.4%-69.6%]) eligible for postoperative VA analysis, and
visual loss (≥0.30 logMAR)occurred in23of the204eyes (11.3%
[95% CI, 7.6%-16.3%]). Of 110 eyes that underwent PPVwith-
out delamination, visual success was achieved by 70 eyes
(63.6% [95% CI, 54.3%-72.0%]), and visual loss occurred in 9
eyes (8.2% [95%CI, 4.4%-14.8%]). Of 94 eyes that underwent
PPVwithdelamination,visual successwasachievedby59eyes
(62.8% [95%CI, 52.7%-71.9%]), and visual loss occurred in 14
eyes (14.9% [95% CI, 9.1%-23.5%]).
Therewas nodifference in the proportion of eyeswith vi-
sual success (P = .90) or visual loss (P = .13) between the eyes
that underwent PPVwith delamination and the eyes that un-
derwent PPVwithout delamination. The occurrence of intra-
operative complications or further PPV did not influence vi-
sual outcome, except for eyes that underwent PPV with
delaminationundergoing furtherPPV,whichhadagreater risk
of 0.3 logMAR (approximately 2 Snellen lines) or more visual
loss (6 of 14 eyes [42.9%] vs 8 of 80 eyes [10.0%]; P = .001).
Usingthe last recordedVA(from6to12months) rather than
best-recordedVA(6-12months)producednochange in theme-
dian VA. The mean logMAR VA (Snellen equivalent) changed
relatively little, from0.74 to0.81 (20/110 to20/130) in the eyes
that underwent PPV without delamination and from 0.78 to
0.83 (20/121 to 20/135) in the eyes that underwent PPV with
delamination.
To assess the risk of bias in theVAdata set (because itwas
incomplete), we compared the demographics of the patients
with VA data recorded in the EMR with the demographics of
the patients without VA data recorded in the EMR and found
nodifference in sex, ethnicity, or age at timeof surgery. There
wasnodifference in themeanpresentingVAbetweeneyeswith
(1.54 logMAR [Snellen equivalent of 20/800]) and eyes with-
out eligible postoperative VA (1.58 logMAR [Snellen equiva-
lent of 20/800]) (P = .57).
Discussion
Our database study reviewed a large number of PPVs under-
taken for diabetic eye disease. The majority of eyes had a
measurable improvement in vision, but the complication rate
was appreciable, particularly in the eyes that underwent PPV
with delamination.
Withexpandingdigitaldatacollection,databasestudiesand
national audits are increasingly being used to document clini-
caloutcomes inareal-worldenvironment.10Theyprovideanew
typeofclinicaldata,andthemethodand interpretationarevery
different fromthoseof clinical trials. For example, the analysis
is limited towhatever data are collected, with the expectation
that data sets are sometimes incomplete.However, they facili-
tate the collection of large data sets, and because the patients
arenotwithin the confines of a clinical trial, the resultsmaybe
more generalizable. By contrast, interventional clinical trials
typically involvenovel interventions,mandatedtreatmentregi-
mens, andexternalmonitoringofoutcomes, and theyoftenoc-
cur in select university hospitals.
Our database studydiffers frommany in that itwas set up
to prospectively collect audit data rather than retrospectively
analyzedata thatwere already collected. TheRCOphthNOD’s
predefinedaimwas to establishnational benchmarks that can
beusedbyclinicians for local audit, in theexpectation that this
will enable patients and physicians to identify issues of con-
cern anddrive quality improvement. Clinicians providedpro-
spective data anonymously to facilitate pooled analysis. In
manyUKspecialties,NHS clinician-level outcomedata are re-
leased into the public domain, but results need to be mea-
sured against national standards, and large database studies
may be better suited to setting “real-world” service bench-
marks than “idealized” clinical trials.
Thecomplication rate in theeyes thatunderwentPPVwith
delaminationwasapproximately 3 timeshigher than the com-
plication rate in eyes that underwent PPVwithout delamina-
tion, with almost 1 in 3 operations associated with a compli-
cation. This was mainly related to retinal tears. This was
reflected in theuse of postoperative tamponade; overall, 43%
ofeyeshadsomesortof tamponade,withagreateruseof long-
acting gases and silicone oil in the eyes that underwent PPV
withdelamination. Siliconeoilwasused in approximately 6%
of cases, similar to some studies11,12 but lower than the 23%
rate reportedbyOstri et al.13 Despite thehigher tear rate in the
delaminationgroup, thepostoperative retinaldetachment rate
was acceptable (2% in both groups), consistentwith previous
series (eTable in the Supplement).11-13
Our VA analysis should be considered exploratory be-
cause, unlike the surgical complication data, VA data collec-
tionwasnotmandated, andnot all hospitalsusedEMRs to rec-
ordpostoperativeVA.Overall, 63%ofeyes improvedbyat least
0.3 logMAR (approximately 2 Snellen lines) after surgery,with
littledifferencebetween theeyes thatunderwentPPVwithde-
lamination and the eyes that underwent PPVwithout delami-
nation. The magnitude of visual improvement is relatively
similar to that reported in the literature (eTable in the
Supplement).11-13
The strengths of our study include its large size, multi-
center data collection, andprospectivedesign.Database stud-
iesmaybe less subject to selectionorpublicationbias thancase
series. The EMRs forced clinicians to record whether or not a
complication occurred and this, combined with anonymized
data collection, may facilitate the recording of surgical com-
plications. Complication data were therefore 100% com-
plete, in that all operation records notedwhether a complica-
tion did or did not occur; however, some cliniciansmay have
elected not to record all complications. The data on the sur-
gical elements are likely to be relatively complete, but it is
possible that some clinicians failed to enter all procedure
elements. Another limitation of our study is that the explor-
atory VA data had much lower levels of completeness. Most
database studiesdonot includeVAdatabecauseVA isnotusu-
ally linked to reimbursement, so in this respect our study is
better than many; however, incomplete VA data collection
raises the prospect of bias, and the results need to be inter-
preted accordingly.
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To look for bias,we compared the baseline demographics
andVAs ineyesofpatientswithVAoutcomedatawith thebase-
linedemographics andVAs in eyesof patientswithoutVAout-
come data, and none was suggested, but this does not elimi-
nate the possibility of bias. We suspect that data collection
reflects variations in the use of the EMR systems among hos-
pitals, with some using EMRs for both the clinic and the op-
erating room,andothersusingEMRs just in theoperating room
and relyingonpaper notes in the clinic. Futuredatabase stud-
iesmight consider the collection of core,mandated data sets,
including VA outcomes, from consecutive patients. Our re-
sults may not be generalizable to other countries, but the
method that we used may serve as a useful template.
Conclusions
In conclusion, the VA data need to be interpreted with cau-
tion, but they suggest that, despite an appreciable complica-
tion rate, most patients benefit from diabetic vitrectomy.
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